

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON AUGUST 27, 2026

References are made to the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of Sunho Biologics, Inc. (the “**Company**”) dated August 13, 2026. Unless context otherwise requires, capitalized terms used in this announcement have the same meanings as those defined in the Circular.

At the EGM held at 3:00 p.m. on Thursday, August 27, 2026, the proposed resolution (the “**Proposed Resolution**”) as set out in the Notice was not passed by the Shareholders by way of poll. The poll results of the Proposed Resolution at the EGM are as follows:

Ordinary Resolution		Number of Votes Cast (approximate percentage of number of votes cast (%))	
		For	Against
1.	THAT Dr. XIA Long (夏龍) be appointed as a non-executive director of the Company with immediate effect upon passing of this ordinary resolution.	0 (0.000000%)	94,000,000 (100.000000%)

As of the date of the EGM, 156,666,800 Shares were in issue. As of the date of the EGM, there were (a) no treasury Shares held by the Company (including any treasury Shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited); and (b) no repurchased Shares which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the EGM.

Accordingly, the total number of Shares entitling Shareholders to attend and vote on the Proposed Resolution at the EGM was 156,666,800 Shares. No Shareholder was required to abstain from voting on the Proposed Resolution at the EGM, nor did any Shareholder indicate in the Circular that he/she/it intended to abstain from voting on or vote against the Proposed Resolution at the EGM, and there were no Shares entitling the holder to attend and abstain from voting in favour of the Proposed Resolution at the EGM as set out in Rule 13.40 of the Listing Rules.

As less than half of the votes from the Shareholders (including proxies) attending and having the rights to vote on the Proposed Resolution at the EGM were cast in favor of the Proposed Resolution, the Proposed Resolution was not passed as an ordinary resolution of the Company.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the poll at the EGM.

Ms. JIANG Xiaoling attended the EGM in person, and Mr. ZHANG Feng, Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen attended the EGM via electronic means.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, August 27, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.